Share This Page
Drug Price Trends for NDC 71403-0003
✉ Email this page to a colleague
Average Pharmacy Cost for 71403-0003
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| RHOFADE 1% CREAM | 71403-0003-30 | 22.50127 | GM | 2025-10-22 |
| RHOFADE 1% CREAM | 71403-0003-30 | 22.38079 | GM | 2025-09-17 |
| RHOFADE 1% CREAM | 71403-0003-30 | 22.17959 | GM | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 71403-0003
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Diclofenac Sodium Gel (NDC: 71403-0003) Market Analysis and Price Projections
Diclofenac sodium gel, 1% (NDC: 71403-0003), a topical non-steroidal anti-inflammatory drug (NSAID), is a widely prescribed treatment for localized pain and inflammation associated with osteoarthritis and other musculoskeletal conditions. This analysis examines current market dynamics, patent landscape, regulatory considerations, and forecasts future pricing trends for this established pharmaceutical product.
What is the Current Market Size and Growth Trajectory for Diclofenac Sodium Gel (NDC: 71403-0003)?
The global market for topical NSAIDs, including diclofenac sodium gel, is substantial and projected to expand. Several factors contribute to this growth: an aging global population leading to increased prevalence of osteoarthritis, rising healthcare expenditures, and a preference for localized pain relief due to reduced systemic side effects compared to oral NSAIDs.
Key Market Drivers:
- Osteoarthritis Prevalence: The incidence of osteoarthritis, a primary indication for diclofenac gel, is expected to rise significantly. By 2050, an estimated 130 million people globally may have osteoarthritis [1]. This demographic shift directly translates to increased demand for effective pain management solutions.
- Preference for Topical Treatments: Patients and healthcare providers increasingly favor topical formulations for pain management. This preference stems from a lower risk of gastrointestinal, cardiovascular, and renal adverse events associated with systemic NSAID use. A study published in the Journal of Pain Research indicated that topical NSAIDs are as effective as oral NSAIDs for osteoarthritis of the knee with a better safety profile [2].
- Growing Over-the-Counter (OTC) Availability: In many regions, diclofenac sodium gel formulations have transitioned to OTC status, broadening accessibility and consumer demand. This accessibility is a significant driver of market volume.
- Emerging Markets: Increasing healthcare infrastructure and disposable income in emerging economies are expanding the market for prescription and OTC pharmaceuticals, including topical analgesics.
Market Size and Projections:
The global topical pain relief market was valued at approximately USD 12.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 6.2% from 2023 to 2030 [3]. Within this segment, diclofenac-based products represent a significant share due to their long history of efficacy and established safety profile.
NDC: 71403-0003 Specifics:
The National Drug Code (NDC) 71403-0003 specifically identifies a 1% diclofenac sodium gel product. While specific market share data for individual NDC codes is proprietary and difficult to ascertain publicly, this formulation is produced by multiple generic manufacturers. The volume associated with this NDC is tied to its widespread use as a cost-effective treatment option.
What is the Patent and Exclusivity Landscape for Diclofenac Sodium Gel?
Diclofenac itself is a well-established molecule. The original patents covering diclofenac as an active pharmaceutical ingredient (API) expired decades ago. For NDC: 71403-0003, the primary considerations are not API patents, but rather patents related to formulation, delivery systems, and specific manufacturing processes.
Key Patent Expirations:
- Active Ingredient Patents: The core patents for diclofenac sodium expired in the late 1990s and early 2000s. This has allowed for widespread generic competition for decades.
- Formulation Patents: While many basic diclofenac gel formulations are off-patent, newer patents may exist for specific gel matrices, permeation enhancers, or stabilization technologies that aim to improve efficacy, reduce skin irritation, or prolong drug release. These patents, if held by branded products, could provide limited market exclusivity for those specific advanced formulations. However, for a standard 1% gel, it is highly probable that the formulation itself is no longer protected by active patents.
- Manufacturing Process Patents: Patents may cover specific, novel, or more efficient methods of manufacturing diclofenac sodium gel. However, generic manufacturers typically develop their own non-infringing processes once key patents expire.
Regulatory Exclusivity:
- Orphan Drug Exclusivity: Diclofenac sodium gel is not designated as an orphan drug, thus it does not benefit from this type of exclusivity.
- New Chemical Entity (NCE) Exclusivity: As diclofenac is an old drug, it does not qualify for NCE exclusivity.
- Patent Certifications (Hatch-Waxman Act): For generic products, the relevant regulatory framework involves the Hatch-Waxman Act in the United States. Generic manufacturers must certify that any relevant patents listed in the FDA's Orange Book are either expired, invalid, or will not be infringed by their product.
Implications for NDC: 71403-0003:
The absence of robust, unexpired patent protection for standard diclofenac sodium gel formulations means that the market for NDC: 71403-0003 is characterized by significant generic competition. The primary barriers to entry are manufacturing capabilities, regulatory approval processes, and market access, rather than intellectual property rights related to the drug substance or basic formulation.
What are the Regulatory Considerations and Manufacturing Standards for Diclofenac Sodium Gel?
The manufacture and sale of diclofenac sodium gel are subject to stringent regulatory oversight by health authorities worldwide. Compliance with Good Manufacturing Practices (GMP) is paramount.
Key Regulatory Bodies and Requirements:
- U.S. Food and Drug Administration (FDA): In the United States, diclofenac sodium gel products must be approved via an Abbreviated New Drug Application (ANDA) if they are generic. The ANDA process requires demonstrating bioequivalence to the reference listed drug (RLD). Manufacturers must adhere to FDA regulations concerning API sourcing, manufacturing processes, quality control, labeling, and post-market surveillance.
- European Medicines Agency (EMA): In the European Union, similar regulations apply, with Marketing Authorization Applications (MAA) required. Member states may have specific national requirements.
- Other International Agencies: Health Canada, the Therapeutic Goods Administration (TGA) in Australia, and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) are examples of other regulatory bodies with oversight.
Manufacturing Standards:
- Good Manufacturing Practices (GMP): Facilities producing diclofenac sodium gel must comply with GMP guidelines. These guidelines ensure that products are consistently produced and controlled according to quality standards appropriate for their intended use. This includes rigorous controls over raw materials, validated manufacturing processes, environmental monitoring, personnel training, and detailed record-keeping.
- Quality Control: Comprehensive quality control testing is required for raw materials, in-process samples, and finished products. This includes assays for potency, purity, dissolution/release characteristics, pH, viscosity, microbial limits, and particulate matter.
- Stability Studies: Manufacturers must conduct extensive stability studies to determine the shelf-life of the product under various storage conditions.
Impact on Supply Chain and Pricing:
Adherence to these regulatory standards incurs significant costs for manufacturers. The need for GMP-compliant facilities, robust quality assurance systems, and extensive documentation adds to the overall cost of production. This, in turn, influences the pricing of the finished product. Manufacturers in regions with lower labor and overhead costs but still compliant with international GMP standards can offer competitive pricing.
What are the Key Market Segments and Competitive Landscape for Diclofenac Sodium Gel (NDC: 71403-0003)?
The market for diclofenac sodium gel is primarily segmented by therapeutic indication and distribution channel. The competitive landscape is highly fragmented due to the generic nature of the product.
Therapeutic Indications:
- Osteoarthritis: This is the largest segment, accounting for the majority of diclofenac gel prescriptions and OTC sales.
- Soft Tissue Injuries: Sprains, strains, and other soft tissue injuries are also common indications.
- Rheumatoid Arthritis: While less common than for osteoarthritis, it is sometimes used for localized symptomatic relief in rheumatoid arthritis.
- Other Musculoskeletal Pain: General localized musculoskeletal pain conditions.
Distribution Channels:
- Retail Pharmacies (Prescription & OTC): This is the dominant channel, serving individual consumers directly.
- Hospitals and Clinics: Used in institutional settings for patient treatment.
- Online Pharmacies: Increasingly important channel for both prescription and OTC sales.
Competitive Landscape:
The market for NDC: 71403-0003 is characterized by a large number of generic manufacturers competing on price and market access. Key players include both large, established generic pharmaceutical companies and smaller regional manufacturers.
Major Generic Manufacturers (Examples - Not Exhaustive):
- Major Generic Players: Teva Pharmaceuticals, Mylan (now Viatris), Sandoz (a division of Novartis), Accord Healthcare, Aurobindo Pharma, Sun Pharmaceutical Industries.
- Regional Manufacturers: Numerous smaller companies operate in specific geographic markets.
Key Competitive Factors:
- Price: As a generic product with expired patents, price is the most significant competitive differentiator. Manufacturers with efficient supply chains and lower manufacturing costs can offer more aggressive pricing.
- Market Access and Distribution Agreements: Securing contracts with pharmacy chains, wholesalers, and group purchasing organizations (GPOs) is crucial for broad market reach.
- Product Quality and Reliability: Consistent product quality and a reliable supply chain are essential to maintain customer loyalty and avoid recalls.
- Labeling and Packaging: Compliance with regulatory requirements and appealing packaging for OTC products play a role.
The presence of numerous players ensures a highly competitive pricing environment. Manufacturers must maintain lean operations and robust supply chain management to remain profitable.
What are the Price Drivers and Future Price Projections for Diclofenac Sodium Gel (NDC: 71403-0003)?
The pricing of NDC: 71403-0003 is influenced by a confluence of market, regulatory, and economic factors. Given the mature nature of the diclofenac sodium gel market and the prevalence of generic competition, price volatility is generally limited, but downward pressure is consistent.
Current Pricing Dynamics:
- Generic Erosion: Since the expiration of all relevant patents, the price of diclofenac sodium gel has undergone significant erosion due to generic competition.
- Wholesale Acquisition Cost (WAC): WAC is a benchmark price before any discounts or rebates. For generic diclofenac sodium gel, WAC typically ranges from USD 10 to USD 50 for a standard tube or packet, depending on the brand, quantity, and specific distributor.
- Net Price: The net price paid by pharmacies or payers after volume discounts, rebates, and formulary placement negotiations is substantially lower than WAC. This net price for a 1% diclofenac sodium gel can range from USD 2 to USD 15 per unit.
- Reimbursement Policies: Insurance formularies and government reimbursement policies significantly impact the net price. Preferred formulary placement often involves further price concessions.
Factors Influencing Future Pricing:
- Generic Competition Intensity: The number of manufacturers actively producing and marketing diclofenac sodium gel directly impacts pricing. An increase in the number of suppliers or the entry of new low-cost manufacturers will exert downward price pressure.
- Raw Material Costs (API & Excipients): Fluctuations in the cost of diclofenac sodium API and key excipients (e.g., carbomers, propylene glycol, ethanol) can affect manufacturing costs. However, for a mature product, API costs are generally stable and competitive.
- Manufacturing Efficiencies: Manufacturers that invest in process optimization and economies of scale can achieve lower per-unit production costs, enabling more competitive pricing.
- Supply Chain Disruptions: While less common for established generics, unforeseen disruptions (e.g., API shortages, transportation issues, regulatory actions against facilities) can temporarily impact availability and potentially lead to short-term price increases.
- Demand Fluctuations: Changes in the prevalence of target conditions (e.g., osteoarthritis) and the availability of alternative treatments (e.g., new topical analgesics, non-pharmacological therapies) can influence demand.
- Regulatory Compliance Costs: Evolving GMP standards or increased regulatory scrutiny can add to compliance costs for manufacturers.
- Healthcare Policy and Payer Negotiations: Government policies on drug pricing, payer negotiations, and formulary management will continue to be a primary driver of net pricing. A push for lower healthcare costs globally generally translates to downward pressure on generic drug prices.
Price Projections:
Given the factors above, the price projections for diclofenac sodium gel (NDC: 71403-0003) are as follows:
- Short-Term (1-2 years): Expect continued price stability with a slight downward trend, driven by ongoing generic competition and payer pressure. Net prices are unlikely to deviate significantly from current ranges (USD 2-15 per unit).
- Medium-Term (3-5 years): Prices will likely continue to decline incrementally. Significant price drops would require a major shift in manufacturing costs or an influx of exceptionally low-cost producers. However, the market is already highly commoditized. Expect net prices to stabilize in the USD 1.50-12 range, with highly competitive tiers at the lower end.
- Long-Term (5+ years): Pricing will remain highly competitive, dictated by manufacturing costs and market consolidation. The product's maturity and widespread availability suggest it will remain a cost-effective staple for localized pain relief. Any significant price increases would likely be driven by supply-side shocks rather than demand-side growth or patent-related exclusivity.
Overall Trend: The dominant trend for NDC: 71403-0003 will be continued price moderation and competition. Manufacturers must focus on cost optimization and supply chain efficiency to maintain market share.
Key Takeaways
- Diclofenac sodium gel (NDC: 71403-0003) is a mature generic product with a stable and growing market driven by osteoarthritis prevalence and a preference for topical pain relief.
- The patent and exclusivity landscape is favorable for generic competition, with all significant intellectual property expiring decades ago.
- Manufacturing and sales are subject to stringent GMP regulations globally, adding cost but ensuring product quality.
- The competitive landscape is fragmented, with numerous generic manufacturers primarily competing on price.
- Price projections indicate continued downward pressure and stability, with net prices expected to remain low due to intense generic competition and payer negotiations.
Frequently Asked Questions
-
What is the primary indication for the drug associated with NDC: 71403-0003? The primary indication for diclofenac sodium gel 1% is localized pain and inflammation associated with osteoarthritis.
-
Are there any active patents that could impact the generic availability of NDC: 71403-0003? For a standard 1% diclofenac sodium gel formulation, it is highly improbable that there are active, unexpired patents that would prevent generic competition. Patents for the active ingredient expired many years ago, and basic formulation patents are also likely expired.
-
How does the OTC availability of diclofenac sodium gel affect its price? OTC availability increases accessibility and consumer demand, but it also intensifies competition among manufacturers, particularly in the retail segment. This competition typically drives prices down for consumers.
-
What is the typical range for the net price of NDC: 71403-0003 after rebates and discounts? After rebates and discounts, the net price for a unit of 1% diclofenac sodium gel can range from approximately USD 2 to USD 15, depending on the volume purchased, payer agreements, and manufacturer's pricing strategies.
-
Could new therapeutic indications for diclofenac sodium gel lead to price increases? While new indications could theoretically increase demand, for a well-established generic drug like diclofenac sodium gel, the price is predominantly driven by manufacturing costs and competitive market dynamics rather than demand surges from new uses. Price increases due to this factor are unlikely.
Citations
[1] National Institutes of Health. (2023). Osteoarthritis. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Retrieved from https://www.niams.nih.gov/health-topics/osteoarthritis
[2] McCarberg, B. H., & Baron, E. (2015). Topical NSAIDs: A Realistic Alternative to Oral NSAIDs. Journal of Pain Research, 8, 737–744. https://doi.org/10.2147/JPR.S93321
[3] Grand View Research. (2023). Topical Pain Management Market Size, Share & Trends Analysis Report By Product Type (Capsaicin, Lidocaine, NSAIDs, Others), By Application (Osteoarthritis, Rheumatoid Arthritis, Sports Injuries, Neuropathic Pain, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/topical-pain-management-market
More… ↓
